Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, voriconazole (Vfend®) cannot be endorsed for use within NHS Wales as prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant recipients. |
||
|
||
Medicine details |
||
| Medicine name | voriconazole (Vfend®) | |
| Formulation | 50 mg film-coated tablet, 200 mg film-coated tablet, 200 mg powder for solution for infusion, 200 mg powder and solvent for solution for infusion, 40 mg/ml powder for oral suspension | |
| Reference number | 1528 | |
| Indication | For use as prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant recipients. |
|
| Company | Pfizer Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 30/10/2014 | |
| Date of issue | 31/10/2014 | |